Michael Burkes Brophy Sells 792 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 792 shares of Natera stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $115,663.68. Following the completion of the sale, the chief financial officer now directly owns 71,869 shares in the company, valued at approximately $10,495,748.76. The trade was a 1.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Price Performance

Shares of NTRA stock opened at $149.63 on Friday. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $161.71 and a two-hundred day simple moving average of $149.27. The stock has a market capitalization of $20.23 billion, a price-to-earnings ratio of -85.02 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of analyst reports. Morgan Stanley raised their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. JPMorgan Chase & Co. upped their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Finally, Royal Bank of Canada began coverage on Natera in a research report on Thursday, March 13th. They set an “outperform” rating and a $251.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $178.12.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the business. Cerity Partners LLC lifted its holdings in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after buying an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Natera during the 3rd quarter worth $385,000. Everence Capital Management Inc. bought a new stake in Natera during the fourth quarter valued at about $573,000. Alpha DNA Investment Management LLC purchased a new position in Natera in the third quarter valued at about $505,000. Finally, First Turn Management LLC purchased a new position in Natera in the third quarter valued at about $19,760,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.